A Rac-PI3Kβ feedback loop drives GPVI-dependent platelet activation Authors: Tom.N. Durrant, James.L. Hutchinson, Carl.J. May, Justin.S. Trory, Samantha.F. Moore, Ingeborg Hers Published: 2026 ABSTRACT SummaryClass I PI3Kβ is critical in controlling platelet activation and preserving thrombus stability under high shear. PI3Kβ is unique among class I phosphoinositide 3-kinases (PI3Ks) in being activated by Rho-family GTPases Rac and Cdc42, positioning it as a potential key link between Rho-family GTPases and platelet signaling. Here, we combined pharmacological inhibition with genetic approaches to define a direct Rho-PI3Kβ signaling axis in mouse platelets. Platelets from knockin mice carrying two point mutations within the Rho-binding domain (RBD) of the PI3Kβ catalytic subunit p110β exhibited impaired GPVI-mediated platelet signaling, functional responses, and spreading on fibrinogen. Pharmacological inhibition with the PI3Kβ-selective inhibitor AZD6482 demonstrated that these responses largely depend on the p110β RBD. Inhibition of Rac/Cdc42 in wild-type platelets phenocopied the knockin defects, supporting a direct role for Rho GTPases in PI3Kβ activation. Conversely, Rac activation was impaired in RBD-mutant and AZD6482-treated platelets, revealing a Rac-PI3Kβ feedback loop that amplifies GPVI-dependent platelet activation. Introduction Class I phosphoinositide 3-kinases (PI3Ks) catalyze the generation of the signaling phospholipid, PtdIns(3,4,5)P3, which regulates a range of binding proteins to drive critical cellular processes underpinning health and disease.1 Class I PI3Ks are heterodimers comprising a regulatory subunit associated with one of four catalytic subunits (p110α, β, δ, or γ), with the latter defining isoform nomenclature.2 While each of the four class I PI3Ks is expressed in blood platelets and contributes to their function, a considerable body of work has defined PI3Kβ as the dominant platelet isoform.3,4,5,6,7 Indeed, the use of selective inhibitors and mice lacking p110β expression or catalytic activity has revealed PI3Kβ to signal downstream of multiple platelet receptors and integrins, playing a key role in platelet activation and stable thrombus formation.8,9 Consequently, the loss of PI3Kβ activity provides protection from occlusive arterial thrombosis in animal models, with minimal bleeding risk, and shows potential as an antithrombotic approach in humans.10,11 More recently, similar approaches demonstrated a role for PI3Kβ in limiting bacterial streptococcal dissemination by promoting platelet interactions with leukocytes.12 While the functional significance of PI3Kβ for platelet function and thrombosis has, therefore, become clear, current understanding of the mechanisms underlying PI3Kβ activation in platelets remains surprisingly limited. PI3Kβ, like PI3Kα and δ, can be activated following the association of its SH2 domain-containing regulatory subunit with phosphotyrosines present on activated receptors or adaptors.13 Furthermore, PI3Kβ, like PI3Kγ, can be activated by G protein-coupled receptor (GPCR) signaling via the direct association of Gβγ subunits with its catalytic subunit.14,15 While these modes of PI3Kβ activation are shared with other class I isoforms, interestingly, Fritsch et al. revealed PI3Kβ to be unique in its preference for activatory input from small GTPases.16 In contrast to PI3Kα, δ, and γ, which receive direct input to their p110 catalytic subunits from GTP-bound Ras family members,16,17,18 PI3Kβ receives activatory input to p110β via the direct binding of the GTP-bound Rho small GTPases, Rac1 and Cdc42.16 Mice expressing PI3Kβ with mutations in the “Rho-binding domain” (RBD) of p110β that ablate Rac/Cdc42 binding show protection from experimental lung fibrosis, while fibroblasts from these mice show impaired PI3Kβ signaling and chemotaxis.16 Furthermore, the p110β RBD is important for PI3Kβ function in myeloid cells, including reactive oxygen species production in bone marrow-derived neutrophils,14 highlighting the significance of Rac/Cdc42 in regulating PI3Kβ-mediating cellular functions. Rac1, Cdc42, and PI3Kβ all play critical roles in platelet biology and, notably, display functional overlap in their support of key platelet processes.3,4,5,6,7,19,20,21,22,23 Despite this, the presence of a direct Rac/Cdc42-PI3Kβ axis in platelets is unknown, although some evidence suggests that a functional relationship between Rho GTPases and a class I PI3K may be present.19,24,25 In this study, we, therefore, used both pharmacological inhibitors and a knockin mouse line expressing p110β with a mutant RBD (homozygous Pik3cb RBD-knockin mice [S205D/K224A], hereafter KI mice or KI platelets) to reveal a bidirectional Rac-PI3Kβ axis in platelets that is critical for GPVI-mediated platelet function. Results Pharmacological and genetic approaches identify a Rho-PI3Kβ axis in mouse platelets To investigate whether Rho-family small GTPases act upstream of class I PI3K in platelets, we used EHT1864 at concentrations titrated to minimize off-target effects26 to inhibit Rac activation in CRP-stimulated mouse platelets. We observed a concentration-dependent inhibition of Rac activity (pIC50 = 5.07 ± 0.001, n = 3 ± SEM, ∼8.5 μM) and Akt phosphorylation on residues T308 and S473 (pIC50 values of 4.86 ± 0.01 and 4.89 ± 0.01, respectively [n = 3 ± SEM, ∼15/12 μM]) (Figures 1A and 1B). In line with its classification as a Rac inhibitor, EHT1864 inhibited the activation of this small GTPase more potently than that of Cdc42, yet still inhibited the latter at concentrations below those commonly used in other studies (IC50 ∼40 μM). These observations support the concept that Rac and/or Cdc42 may regulate the activation of a class I PI3K in platelets. To evaluate whether this regulation is through direct interaction between Rac/Cdc42 and p110β, we utilized KI mice ablating the ability of this PI3K to interact with Rac and Cdc42 (Figure 1C).15 These mice displayed unaltered hematological parameters (Table 1), and their platelets expressed the class I PI3K catalytic and regulatory subunits (p110α, β, γ, δ, p85) at comparable levels to their wild-type (WT) counterparts (Figures 1D and 1E).Figure 1Pharmacological and genetic approach to identify a Rho-PI3Kβ axis in mouse platelets(A) Washed platelets were stimulated as indicted before lysis in either 4× NuPAGE SDS-PAGE sample buffer containing 0.5 M DTT (Lysates) or Rac/Cdc42 lysis buffer (bait pull-down [PD]). Lysates and GST-PAK1 bait PDs were analyzed by SDS-PAGE/western blotting.(B) Pre-treatment of platelets with the Rac inhibitor EHT1864 (10 min) prior to stimulation with 2 μg/mL CRP-XL (2 min) resulted in a concentration-dependent reduction in GTP-bound (active) Rac and Cdc42. Notably, EHT1864 treatment also led to a concentration-dependent reduction in the phosphorylation of the class I PI3K effector, Akt, suggesting a role for Rac and/or Cdc42 upstream of class I PI3K in mouse platelets. Data are expressed as mean ± SEM (n = 4). Concentration-response curves were fitted with a four-parameter logistic equation using GraphPad Prism.(C) To explore a potential Rho-PI3Kβ axis, platelets were derived from knockin (KI) mice harboring two mutations (S205D and K224A) in their Rho-binding domain (RBD), rendering them unable to interact with active Rac or Cdc42. Washed platelets were lysed in 4× NuPAGE SDS-PAGE sample buffer containing 0.5 M DTT before analysis by SDS-PAGE/western blotting. Immunoblotting with subunit-specific antibodies determined that mutation of PI3Kβ in platelets did not alter the expression of p110β or other class I PI3K subunits.(D and E) (D) A representative blot, with (E) displaying n = 3 quantification, mean ± SEM.Table 1Whole blood counts and platelet surface receptor expression in WT and KI miceParameterWT meanWT (SEM)KI meanKI (SEM)np valuePlatelets 103/mm36651372846140.283MPV mm35.100.045.240.07140.054WBC 103/mm38.350.347.900.48140.431RBC 106/mm39.300.239.530.24140.530Integrin αIIb MFI4974366451939950.125GPVI mfi818599019750.188Complete blood counts were conducted using a Pentra ES60 (Horiba) and adjusted for anticoagulant volume.Surface expression of integrin αIIb (CD41) and GPVI was measured in resting platelets by flow cytometry using FITC-conjugated antibodies.Student’s t test and Wilcoxon test were used to test for statistical differences between genotypes. MFI, Median Fluorescent Intensity Pharmacological and genetic approach to identify a Rho-PI3Kβ axis in mouse platelets (A) Washed platelets were stimulated as indicted before lysis in either 4× NuPAGE SDS-PAGE sample buffer containing 0.5 M DTT (Lysates) or Rac/Cdc42 lysis buffer (bait pull-down [PD]). Lysates and GST-PAK1 bait PDs were analyzed by SDS-PAGE/western blotting. (B) Pre-treatment of platelets with the Rac inhibitor EHT1864 (10 min) prior to stimulation with 2 μg/mL CRP-XL (2 min) resulted in a concentration-dependent reduction in GTP-bound (active) Rac and Cdc42. Notably, EHT1864 treatment also led to a concentration-dependent reduction in the phosphorylation of the class I PI3K effector, Akt, suggesting a role for Rac and/or Cdc42 upstream of class I PI3K in mouse platelets. Data are expressed as mean ± SEM (n = 4). Concentration-response curves were fitted with a four-parameter logistic equation using GraphPad Prism. (C) To explore a potential Rho-PI3Kβ axis, platelets were derived from knockin (KI) mice harboring two mutations (S205D and K224A) in their Rho-binding domain (RBD), rendering them unable to interact with active Rac or Cdc42. Washed platelets were lysed in 4× NuPAGE SDS-PAGE sample buffer containing 0.5 M DTT before analysis by SDS-PAGE/western blotting. Immunoblotting with subunit-specific antibodies determined that mutation of PI3Kβ in platelets did not alter the expression of p110β or other class I PI3K subunits. (D and E) (D) A representative blot, with (E) displaying n = 3 quantification, mean ± SEM. Table 1Whole blood counts and platelet surface receptor expression in WT and KI miceParameterWT meanWT (SEM)KI meanKI (SEM)np valuePlatelets 103/mm36651372846140.283MPV mm35.100.045.240.07140.054WBC 103/mm38.350.347.900.48140.431RBC 106/mm39.300.239.530.24140.530Integrin αIIb MFI4974366451939950.125GPVI mfi818599019750.188Complete blood counts were conducted using a Pentra ES60 (Horiba) and adjusted for anticoagulant volume.Surface expression of integrin αIIb (CD41) and GPVI was measured in resting platelets by flow cytometry using FITC-conjugated antibodies.Student’s t test and Wilcoxon test were used to test for statistical differences between genotypes. MFI, Median Fluorescent Intensity Whole blood counts and platelet surface receptor expression in WT and KI mice Complete blood counts were conducted using a Pentra ES60 (Horiba) and adjusted for anticoagulant volume. Surface expression of integrin αIIb (CD41) and GPVI was measured in resting platelets by flow cytometry using FITC-conjugated antibodies. Student’s t test and Wilcoxon test were used to test for statistical differences between genotypes. MFI, Median Fluorescent Intensity As a primary assessment of whether loss of Rac1/Cdc42 input to PI3Kβ would affect platelet function, we assessed the activation of the major platelet integrin αIIbβ3, the receptor responsible for platelet aggregation, in response to GPVI and PAR-4 receptor stimulation. KI mice displayed a significant defect in CRP-induced integrin αIIbβ3 activation at both low and high concentrations of this GPVI agonist (Figure 2A), while a clear but more modest defect in integrin αIIbβ3 activation was observed in response to PAR-4 activation with AYPGKF peptide (Figure 2B). A small but significant defect was also observed for integrin αIIbβ3 activation in KI platelets in response to thrombin stimulation (Figure S1). In support of these observations, pretreatment of platelets with the PI3Kβ-selective inhibitor, AZD6482, confirmed the important role of this class I PI3K isoform in integrin αIIbβ3 activation, in agreement with previous work.3,7 Strikingly, our data assessing both WT and KI platelets in the presence and absence of AZD6482 revealed PI3Kβ′s role in integrin αIIbβ3 activation to be largely dependent on the RBD of p110β (Figures 2A and 2B). Additionally, CRP- and PAR1-mediated human platelet responses were reduced to comparable levels by the Rac inhibitor EHT1864 and the PI3Kβ inhibitor AZD6482, with no additional effect when combined, suggesting that a similar regulatory mechanism may also operate in human platelets (Figure S2).Figure 2KI platelets display defects in integrin αIIbβ3 activation and α-granule secretionWashed platelets were pre-treated with vehicle or AZD6482 (100 nM) for 10 min, before stimulation with the indicated agonists (10 min) in the presence of a PE-conjugated antibody (JON/A) directed against the high-affinity form of integrin αIIbβ3 (A and B) and a fluorescein isothiocyanate (FITC)-conjugated antibody (Wug.E9) for the α-granule marker CD62P (P-selectin) (C and D) before fixation and analysis on a BD Accuri C6+. Integrin αIIbβ3 activation and α-granule secretion were reduced in KI platelets compared to WT, with the use of AZD6482 revealing PI3Kβ′s role in these processes to be almost entirely dependent on the RBD of p110β. Data are expressed as mean ± SEM (n = 5). A two-way ANOVA (variable 1 = genotype, variable 2 = agonist concentration) followed by Bonferroni’s multiple comparison test was used to test statistical significance. α = 0.05. The p values in the figure indicate whether a difference exists between genotypes. Asterisk notation relates to the multiple comparison test indicating where the differences exist. ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Absence of a symbol on the graph does not imply non-significance for other contrasts. All within-concentration, Šidák-adjusted pairwise comparisons among WT-Veh, WT + AZD6482, KI-Veh, and KI + AZD6482 are reported in Table S1. KI platelets display defects in integrin αIIbβ3 activation and α-granule secretion Washed platelets were pre-treated with vehicle or AZD6482 (100 nM) for 10 min, before stimulation with the indicated agonists (10 min) in the presence of a PE-conjugated antibody (JON/A) directed against the high-affinity form of integrin αIIbβ3 (A and B) and a fluorescein isothiocyanate (FITC)-conjugated antibody (Wug.E9) for the α-granule marker CD62P (P-selectin) (C and D) before fixation and analysis on a BD Accuri C6+. Integrin αIIbβ3 activation and α-granule secretion were reduced in KI platelets compared to WT, with the use of AZD6482 revealing PI3Kβ′s role in these processes to be almost entirely dependent on the RBD of p110β. Data are expressed as mean ± SEM (n = 5). A two-way ANOVA (variable 1 = genotype, variable 2 = agonist concentration) followed by Bonferroni’s multiple comparison test was used to test statistical significance. α = 0.05. The p values in the figure indicate whether a difference exists between genotypes. Asterisk notation relates to the multiple comparison test indicating where the differences exist. ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Absence of a symbol on the graph does not imply non-significance for other contrasts. All within-concentration, Šidák-adjusted pairwise comparisons among WT-Veh, WT + AZD6482, KI-Veh, and KI + AZD6482 are reported in Table S1. We next sought to assess platelet secretion, a process critical for the amplification of platelet signaling and for the recruitment of platelets to a growing thrombus. Measurement of CD62P (P-selectin) surface expression yielded similar results to integrin αIIbβ3 activation, revealing a marked defect in CRP-induced platelet α-granule secretion in KI mouse platelets in response to CRP, with the use of AZD6482 again revealing PI3Kβ′s role in this process to be largely dependent on its Rac1/Cdc42-binding domain (Figure 2C). PAR-mediated α-granule secretion is known to be less dependent on PI3K activation,27 and in agreement with this, the extent of inhibition with AZD6482 and in KI platelets in response to AYPGKF was minimal (Figure 2D). Mutation of the PI3Kβ RBD leads to defects in platelet aggregation and dense granule secretion To further explore the role of the Rac1/Cdc42-PI3Kβ axis in platelet functional pathways, we examined the ability of CRP, and the PAR ligands AYPGKF and thrombin, to induce aggregation of KI platelets. GPVI-mediated aggregation of KI platelets was impaired across a range of CRP concentrations (Figure 3A), while aggregation in response to PAR-4 activation remained unaffected (Figure 3B). Platelet aggregation is highly dependent on calcium-driven secretion of ADP from platelet δ-granules,28 and accordingly, we observed a significant reduction in the area under the curve for GPVI-mediated Ca2+ mobilization in KI platelets (Figure 3C), with the same observed for AYPGKF (Figure 3D) and thrombin (Figure 3E). Ca2+ mobilization kinetics in KI platelets, however, was unaffected (Figures 3Cii–Eii and S3), indicating that mainly peak Ca2+ responses are reduced. Interestingly, while the defect in CRP-mediated Ca2+ mobilization correlated with a significant reduction in δ-granule secretion (Figure 3F), the same was not observed upon PAR-4 receptor activation (Figures 3G and 3H).Figure 3GPVI-mediated platelet aggregation, Ca2+ mobilization, and δ-granule secretion are reduced in KI platelets(A and B) Washed platelets were stimulated with CRP (A) or AYPGKF (B) under stirring conditions and aggregation monitored using LTA, revealing a platelet aggregation defect in KI platelets downstream of GPVI but not PAR-4. Data are expressed as mean ± SEM (n = 6).(C–E) (i) Platelets were loaded with the intracellular calcium indicator Fura-PE3 and agonist-induced changes in [Ca2+]i monitored using a Tecan Infinite 200 PRO plate reader, revealing a defect in response to CRP, AYPGKF, and thrombin treatment in KI platelets, measured as area under the curve ([AUC], n = 3, average ±SEM). (ii) Ca2+ traces following platelet stimulation with 10 μg/mL CRP, 300 μM AYPGKF, and 3 U/mL thrombin (mean ± SEM, n = 3). A representative experiment showing Ca2+ traces for all agonist concentrations can be found in Figure S3.(F–H) Washed platelets were stimulated in the presence of luciferin/luciferase reagent (CHRONO-LUME). Luminescence was measured using a Tecan Infinite 200 PRO plate reader. This revealed secretion of the δ-granule cargo ATP to be reduced in KI platelets at multiple concentrations of CRP, but not in response to AYPGKF or thrombin. Data are expressed as mean ± SEM (n = 3). Data were analyzed by two-way ANOVA with Šidák post-test for significance. Curves were fitted by nonlinear regression. Asterisk notation indicates statistical significance: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗p < 0.0001. GPVI-mediated platelet aggregation, Ca2+ mobilization, and δ-granule secretion are reduced in KI platelets (A and B) Washed platelets were stimulated with CRP (A) or AYPGKF (B) under stirring conditions and aggregation monitored using LTA, revealing a platelet aggregation defect in KI platelets downstream of GPVI but not PAR-4. Data are expressed as mean ± SEM (n = 6). (C–E) (i) Platelets were loaded with the intracellular calcium indicator Fura-PE3 and agonist-induced changes in [Ca2+]i monitored using a Tecan Infinite 200 PRO plate reader, revealing a defect in response to CRP, AYPGKF, and thrombin treatment in KI platelets, measured as area under the curve ([AUC], n = 3, average ±SEM). (ii) Ca2+ traces following platelet stimulation with 10 μg/mL CRP, 300 μM AYPGKF, and 3 U/mL thrombin (mean ± SEM, n = 3). A representative experiment showing Ca2+ traces for all agonist concentrations can be found in Figure S3. (F–H) Washed platelets were stimulated in the presence of luciferin/luciferase reagent (CHRONO-LUME). Luminescence was measured using a Tecan Infinite 200 PRO plate reader. This revealed secretion of the δ-granule cargo ATP to be reduced in KI platelets at multiple concentrations of CRP, but not in response to AYPGKF or thrombin. Data are expressed as mean ± SEM (n = 3). Data were analyzed by two-way ANOVA with Šidák post-test for significance. Curves were fitted by nonlinear regression. Asterisk notation indicates statistical significance: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗p < 0.0001. KI platelets show defective spreading on fibrinogen Rac1 and Cdc42 are important regulators of cytoskeletal dynamics and are essential for platelet spreading through the formation of lamellipodia and filopodia, respectively.19,20,21,22 Similarly, PI3Kβ activity has been implicated in platelet spreading,5 and so we sought to determine the importance of the Rac1/Cdc42-PI3Kβ axis to this process. In agreement with previous observations,29 the mouse platelets displayed limited spreading on fibrinogen in the absence of co-stimulation, but spreading was significantly enhanced upon treatment of platelets with CRP or thrombin (Figure 4A). Notably, CRP-induced spreading on fibrinogen was significantly impaired in KI platelets, equivalent to the preincubation of platelets with the PI3Kβ inhibitor AZD6482 (Figures 4A and 4B), demonstrating a clear role for the Rho-PI3Kβ axis in platelet spreading. In line with our other assessments of platelet function, thrombin-induced spreading on fibrinogen was impaired to a smaller extent than CRP in the KI mouse platelets (Figures 4A and 4B). In contrast to fibrinogen, platelet spreading on collagen remained unaffected either with KI mouse platelets or with WT platelets in the presence of AZD6482 (Figure S4), in agreement with previous work demonstrating that PI3Kβ activity is not required for platelet spreading on collagen.30Figure 4KI platelets show defective spreading on fibrinogen following costimulation with CRPWT and KI platelets were preincubated with 100 nM AZD6482 or vehicle control for 10 min before being allowed to spread on 100 μg/mL fibrinogen for 60 min at 37°C in 96-well glass-bottomed plates, in the presence of 1 μg/mL CRP, 0.1U/mL thrombin, or vehicle. After fixation, platelets were stained with ActinGreen and imaged on a Leica widefield microscope. A representative image of each condition is shown in (A), with quantification expressed as mean ± SEM shown in (B). Quantification represents 3 independent biological replicates, with a minimum of 5 distinct fields of view analyzed for each condition per biological replicate. Platelet area was assessed by the extent of ActinGreen staining per platelet using ImageJ software. Data were analyzed by two-way ANOVA with Šidák post-test for significance (p < 0.01). Scale bars, 20 μm. KI platelets show defective spreading on fibrinogen following costimulation with CRP WT and KI platelets were preincubated with 100 nM AZD6482 or vehicle control for 10 min before being allowed to spread on 100 μg/mL fibrinogen for 60 min at 37°C in 96-well glass-bottomed plates, in the presence of 1 μg/mL CRP, 0.1U/mL thrombin, or vehicle. After fixation, platelets were stained with ActinGreen and imaged on a Leica widefield microscope. A representative image of each condition is shown in (A), with quantification expressed as mean ± SEM shown in (B). Quantification represents 3 independent biological replicates, with a minimum of 5 distinct fields of view analyzed for each condition per biological replicate. Platelet area was assessed by the extent of ActinGreen staining per platelet using ImageJ software. Data were analyzed by two-way ANOVA with Šidák post-test for significance (p < 0.01). Scale bars, 20 μm. Signaling in response to multiple platelet agonists is suppressed in KI platelets Having characterized the functional defects in platelets lacking the Rho-PI3Kβ axis, we next aimed to further investigate the effect on the underlying signaling pathways. Stimulation of platelets with a range of agonists for 2 min revealed that mutation of the RBD of PI3Kβ results in a significant reduction in the phosphorylation of Akt in response to thrombin, CRP, and ADP (Figures 5A and 5B). Signaling to Akt in response to platelet stimulation with the thromboxane A2 receptor agonist, U46619, or with IGF-1, remained unchanged in KI mouse platelets. While both PI3Kα and PI3Kβ are known to support IGF-1 signaling to Akt,34 these results indicate that the latter component may be independent of the RBD of p110β. PLCγ2 and other signaling pathway components displayed small but non-significant defects in phosphorylation at this time point. In agreement with the reduction in agonist-induced Ca2+ mobilization, we also observed a reduction in phosphorylation of the PKC substrate Pleckstrin (Figure 5B).Figure 5KI platelets show impaired signaling in response to multiple platelet agonists(A–F) Washed platelets were stimulated as indicated before lysis in 4× SDS PAGE sample buffer containing 0.5 M DTT followed by analysis by SDS-PAGE/western blotting.(A and B) Phosphorylation of Akt at S473 and T308 and phosphorylation of the PKC substrate pleckstrin in response to thrombin and CRP-XL were significantly reduced in KI mouse platelets, while other agonist responses remained unchanged. CRP-mediated phosphorylation of Syk and LAT was unaffected in KI platelets (Figure S6).(C–F) Kinetic time-course analysis of 2 μg/mL CRP stimulation reveals a defect in signaling to multiple cellular effectors in KI platelets (C and D) and platelets treated with AZD6482 (E and F). Data are expressed as mean ± SEM (n = 3). In contrast, phosphorylation of Syk and LAT was unaffected in KI platelets (Figure S6). Talin was used as a loading control, as the total expression levels of the signaling proteins analyzed do not change over this short stimulation time frame,31,32,33 making it an appropriate normalization marker. Immunoblots were quantified using Image Studio v.5.2. Statistical significance was determined using multiple t tests and the Bonferroni-Šidák method. α = 0.05. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. KI platelets show impaired signaling in response to multiple platelet agonists (A–F) Washed platelets were stimulated as indicated before lysis in 4× SDS PAGE sample buffer containing 0.5 M DTT followed by analysis by SDS-PAGE/western blotting. (A and B) Phosphorylation of Akt at S473 and T308 and phosphorylation of the PKC substrate pleckstrin in response to thrombin and CRP-XL were significantly reduced in KI mouse platelets, while other agonist responses remained unchanged. CRP-mediated phosphorylation of Syk and LAT was unaffected in KI platelets (Figure S6). (C–F) Kinetic time-course analysis of 2 μg/mL CRP stimulation reveals a defect in signaling to multiple cellular effectors in KI platelets (C and D) and platelets treated with AZD6482 (E and F). Data are expressed as mean ± SEM (n = 3). In contrast, phosphorylation of Syk and LAT was unaffected in KI platelets (Figure S6). Talin was used as a loading control, as the total expression levels of the signaling proteins analyzed do not change over this short stimulation time frame,31,32,33 making it an appropriate normalization marker. Immunoblots were quantified using Image Studio v.5.2. Statistical significance was determined using multiple t tests and the Bonferroni-Šidák method. α = 0.05. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Kinetic analysis reveals further alterations in GPVI signaling in KI platelets Our results agree with previous work demonstrating that PI3Kβ holds an important role in regulating platelet signaling and function downstream of GPVI.7,8 To further investigate the aberrant signaling of KI platelets in response to GPVI activation, we examined the phosphorylation of a range of effectors in response to CRP stimulation across multiple time points. This confirmed that the phosphorylation of Akt is significantly attenuated in KI platelets at all time points (Figures 5C and 5D). Phosphorylation of signaling components proximal to GPVI, such as LAT, Syk, and PLC, was unaffected in KI platelets at early (0.5 min) time points, demonstrating that primary GPVI signaling is intact. Interestingly, however, their phosphorylation became more transient over time in KI platelets compared to WT platelets, indicating that the Rac-PI3Kβ axis is involved in sustaining GPVI signaling. These results were largely recapitulated using the PI3Kβ-selective inhibitor, AZD6482 (Figures 5E and 5F), demonstrating that the Rac/PI3Kβ axis is a major mechanism of PI3Kβ regulation in platelets. The Rho-PI3Kβ axis in platelets is bidirectional Given that the mutations in the RBD of p110β in the KI mice ablate interaction with Rac1 and Cdc42, and that these small GTPases are also integrated components of GPVI-mediated platelet activation,22 we next sought to assess their activation in KI platelets. Examination of GTP-bound Rac and Cdc42, and the phosphorylation of PAK2, a downstream effector, revealed that the activation of all three was largely impaired in CRP-stimulated KI platelets across a range of time points (Figure 6A). This was most striking for Rac activation, while Cdc42 activation was slower and more sustained, showing only a significant defect at later time points (Figure 6A). To assess whether germline mutation of the Rac/Cdc42-interaction domain of p110β may have resulted in long-term compensatory effects, we confirmed that the observed changes in agonist-stimulated levels of GTP-Rac and -Cdc42 were not due to a change in the expression of these small GTPases in KI mouse platelets (Figure S5). Studies where PI3Kβ function was acutely inhibited by AZD6482 confirmed a significant defect in both Rac and Cdc42 activation in response to platelet activation with CRP (Figure 6B). Thus, through both pharmacological and genetic approaches, we demonstrate the interdependence of Rac/Cdc42 and PI3Kβ activation in platelets, and the importance of this axis for platelet function.Figure 6The Rho-PI3Kβ axis in mouse platelets is bidirectionalWashed platelets were stimulated as indicated before lysis in either 4× NuPAGE SDS-PAGE sample buffer containing 0.5 M DTT (lysates) or Rac/Cdc42 lysis buffer (bait pull down [PD]). Lysates and GST-PAK1 bait PDs of active (GTP bound) Rac and were analyzed by SDS-PAGE/western blotting. Data in graphs are expressed as mean ± SEM (n = 3).(A) Analysis reveals significant inhibition of Rac activation and of phosphorylation of the downstream effector PAK2, in KI platelets in response to 2 μg/mL CRP stimulation across multiple time points. The talin blot was used as a protein input control and aligns with the experiment presented in Figure 5C.(B) Use of the PI3Kβ-selective inhibitor AZD6482 confirms the dependence of Rac activation, and to a lesser extent, Cdc42 activation, upon PI3Kβ activity. The talin blot was used as a protein input control and aligns with the experiment presented in Figure 5E. Data are expressed as mean ± SEM. A two-way ANOVA followed by Bonferroni’s multiple comparison test was used to test statistical significance. α = 0.05. Asterisk notation relates to the multiple comparison test indicating where the differences exist. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. The Rho-PI3Kβ axis in mouse platelets is bidirectional Washed platelets were stimulated as indicated before lysis in either 4× NuPAGE SDS-PAGE sample buffer containing 0.5 M DTT (lysates) or Rac/Cdc42 lysis buffer (bait pull down [PD]). Lysates and GST-PAK1 bait PDs of active (GTP bound) Rac and were analyzed by SDS-PAGE/western blotting. Data in graphs are expressed as mean ± SEM (n = 3). (A) Analysis reveals significant inhibition of Rac activation and of phosphorylation of the downstream effector PAK2, in KI platelets in response to 2 μg/mL CRP stimulation across multiple time points. The talin blot was used as a protein input control and aligns with the experiment presented in Figure 5C. (B) Use of the PI3Kβ-selective inhibitor AZD6482 confirms the dependence of Rac activation, and to a lesser extent, Cdc42 activation, upon PI3Kβ activity. The talin blot was used as a protein input control and aligns with the experiment presented in Figure 5E. Data are expressed as mean ± SEM. A two-way ANOVA followed by Bonferroni’s multiple comparison test was used to test statistical significance. α = 0.05. Asterisk notation relates to the multiple comparison test indicating where the differences exist. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Discussion There is substantial evidence from both genetic animal models and pharmacological studies that class I PI3Kβ regulates platelet function and is essential for thrombus integrity at high shear conditions.6,30,35,36,37 Unlike other class I PI3Ks, PI3Kβ only receives activatory input from Rho-family GTPases such as Cdc42 and Rac, as opposed to Ras-family members.38 Given the limited understanding of how class I PI3Kβ is activated in human platelets, we aimed to evaluate the contribution of Rho GTPases in regulating PI3Kβ activity by using a mouse model containing two mutations that impair Rho binding to PI3Ks and, therefore, will interfere with Rho-mediated PI3K regulation. Using these KI mice and pharmacological inhibitors, we examined how PI3Kβ is regulated downstream of GPVI and PAR-4 thrombin receptors and determined its effect on platelet function. This study provides evidence for the critical role of the Rac-PI3Kβ axis in the regulation of platelet function. We have utilized pharmacological tools and a transgenic mouse model to elucidate that Rho GTPases, specifically Rac, directly activate PI3Kβ in platelets. The RBD, contained within the p110β catalytic domain of PI3Kβ, is central to this regulation. When this signaling axis is disrupted, there are significant alterations to platelet signaling and activation. Additionally, we show here that this regulation is bidirectional, which is indicative of a sophisticated feedback mechanism that serves to amplify and stabilize platelet responses. Previous studies have reported that Rac can impact the activity of PLCγ2.39,40 Although rapid phosphorylation of PLCγ2 (sub-90 s) was not affected in Rac −/− mice, its overall activity was impaired.39 We have confirmed this observation in our study and furthermore established that Rac/Cdc42-mediated regulation of PI3Kβ underlies PLCγ2 regulation. Early PLCγ2 phosphorylation was not affected in KI platelets; however, later phosphorylation (>2 min) and PLCγ2 downstream signaling such as Ca2+ mobilization and phosphorylation of the PKC substrate pleckstrin were significantly impaired. These findings were largely recapitulated by pharmacological methods using a PI3Kβ inhibitor, indicating a key role for Rac/Cdc42 in the regulation of PLCγ2 activity via the Rho/PI3βK axis. The defects in PI3K signaling observed in the KI platelets were furthermore phenocopied by pharmacological inhibition of Rac and Cdc42 in WT platelets, supporting their key role in the activation of PI3Kβ via the RBD of p110β. PtdIns (3,4,5)P3 generation then can potentially further support PH-domain-mediated membrane targeting and activation of PLCγ2.41 We observed a marked reduction in CRP-mediated Rac activation in KI platelets, with Cdc42 being minimally affected, indicating that activation of PI3Kβ contributes to a positive feedback loop that mainly amplifies Rac activation. The precise mechanism by which PI3Kβ regulates Rac remains unclear; however, our previous studies demonstrated that PtdIns (3,4,5)P3 interacts with guanine nucleotide exchange factors (GEFs) in platelets, including multiple members of the DOCK family, many showing specificity for Rac over Cdc42.1,42 This suggests that PtdIns (3,4,5)P3 can lead to further Rac activation by recruiting GEFs to the membrane via their DHR1 domains.43,44 In our proposed model, the relationship between PI3Kβ and Rac is, therefore, bidirectional with Rac feeding back and amplifying PI3Kβ signaling. Our findings, in conjunction with existing literature, provide strong support for the following bidirectional signaling pathways initiated by GPVI. Activation of the Src family of kinases results in phosphorylation of the FcRy chain and subsequent activation of Syk. Downstream phosphorylation of the adaptor protein Lat creates binding sites for a multitude of proteins, including the PH domains of the p85 subunit of PI3K, which leads to activation of the associated catalytic p110β subunit.45 Platelets lacking p85 indeed exhibited a marked defect in GPVI-mediated PI3K activation, phosphorylation and activation of PLCγ2, as well as platelet aggregation.45 This effect was, furthermore, selective to GPVI signaling, with platelet aggregation by other agonists such as thrombin, ADP, and U46619 remaining unaffected.45 This may reflect the importance of localized PtdIns(3,4,5)P3 production in the recruitment of key signaling proteins, such as Btk, to the Lat complex, but potentially also PtdIns(3,4,5)P3-mediated recruitment of Rac/Cdc42 GEFs.1 The latter, together with the localization of Vav1/3 Rac GEFs to adaptor proteins in the Lat signalosome,46 may underlie the initial Rac/Cdc42 activation downstream of GPVI. Regardless of the precise mechanism, this initial Rac/Cdc42 activation further enhances PI3Kβ activity by directly interacting with the RBD of p110β. This promotes localized production of PtdIns(3,4,5)P3, thereby reinforcing downstream Rac activation through a positive feedback loop. Cdc42 activation is minimally affected in KI platelets and only at later time points, suggesting that the feedback loop mainly involves Rac activity. The importance of the Rac/PI3Kβ positive feedback loop is demonstrated by the finding that only residual low levels of phosphorylation of the PI3K downstream substrate Akt, GTP-Rac levels and downstream P-PAK2, Ca2+ mobilization, and phosphorylation of the PKC substrate pleckstrin were detected in KI platelets. In contrast, upstream GPVI proximal phosphorylation of Syk and Lat was unaffected at early time points, demonstrating that primary GPVI signaling is left intact. Disruption of the positive feedback loop primarily impaired platelet responses downstream of GPVI. A significant reduction in integrin αIIbβ3 activation was observed in response to CRP-induced stimulation of the GPVI receptor. In contrast, while there was a modest decrease in integrin αIIbβ3 activation and P-selectin expression following PAR-4, the effect was not observed with the physiological ligand, thrombin. Similarly, δ-granule secretion was markedly impaired upon GPVI stimulation, whereas PAR-4 and thrombin-mediated secretion remained unaltered. Interestingly, Ca2+ mobilization in KI platelets in response to PAR-4 stimulation and thrombin was significantly reduced, although to a lesser extent than to CRP, suggesting that a similar Rac-PI3Kβ feedback loop exists downstream of the PAR-4 receptor. It is, however, evident that the amplification of PI3Kβ signaling via the interaction of Rac with the RBD domain of p110β is of greater importance in functional processes triggered by the GPVI receptor versus the PAR-4 receptor. These functional findings are consistent with previous studies using p110β-deficient platelets and PI3Kβ inhibitors, showing that GPVI-mediated platelet function is highly dependent on PI3Kβ, while PAR-mediated pathways are less affected.3,4,5,47,48 A comparable Rac-PI3Kβ-dependent positive feedback loop may also be important downstream of the hemITAM receptor CLEC2, consistent with the finding that generic and p110β-selective PI3kinase inhibitors block CLEC2-mediated platelet responses.49,50 Together, our data elucidate the intricate relationship between Rac and PI3Kβ in platelets. We demonstrate that the Rac-PI3Kβ positive feedback loop is crucial in the robust amplification of GPVI-mediated PI3Kβ signaling, promoting enhanced downstream activation and platelet aggregation. This mechanism likely enables the platelets to finely adjust their activation in response to different stimuli. Gaining deeper insight into the Rac-PI3Kβ axis may reveal new therapeutic strategies to target this regulatory pathway and modulate thrombotic responses. Limitations of the study A limitation of the mouse model in which the RBD of p110β is mutated to prevent Rac binding is that this interaction cannot readily be examined in an equivalent genetic manner in human platelets, as their anucleate nature prevents targeted modification of endogenous signaling proteins. In addition, interspecies differences in platelet signaling may affect the extent to which Rac-PI3Kβ regulation is conserved. Nonetheless, pharmacological inhibition of Rac or PI3Kβ similarly reduced CRP- and PAR1-induced responses in human platelets, with no significant additional effect when combined, suggesting a common signaling pathway. Although pharmacological approaches do not define mechanism as precisely as the genetic model, these findings support the potential translational relevance of this regulatory pathway in human platelets. We used approximately equal numbers of male and female mice, and comparisons were made in an age- and sex-matched manner. However, the influence of sex cannot be determined due to limited power. Resource availability Lead contact Further information and requests for resources should be directed to the lead contact, Ingeborg Hers (i.hers@bristol.ac.uk). Materials availability This study did not generate new unique reagents. Data and code availability •All data generated in this paper will be shared by the lead author upon request.•This paper does not record original code.•Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. •All data generated in this paper will be shared by the lead author upon request. All data generated in this paper will be shared by the lead author upon request. •This paper does not record original code. This paper does not record original code. •Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. Acknowledgments We are grateful to Dr. Roger Hunter for superb experimental support during the course of this study. We would also like to thank Profs. Len Stephens and Phil Hawkins from the Babraham Institute in Cambridge, UK, for providing us with the mice expressing endogenous p110β harboring two mutations (S205D and K224A) in the RBD domain. Funding: BBSRC; BB/X017176/1, BHF; PG/16/3/31833, PG/16/21/32083, and FS/16/27/32213. Author contributions Conceptualization, T.N.D., S.F.M., and I.H.; data curation, T.N.D. and S.F.M.; formal analysis, T.N.D., J.L.H., J.S.T., and S.F.M.; funding acquisition, I.H.; investigation, T.N.D., J.L.H., J.S.T., and S.F.M.; supervision, I.H.; writing – original draft preparation, T.N.D.; writing – review and editing, C.J.M. and I.H. Declaration of interests The authors declare no competing interests. STAR★Methods Key resources table REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesRabbit monoclonal anti-phospho-Akt(T308)Cell Signaling Tech. (New England Biolabs, Hitchin, UK)Cat #13038, D25E6; RRID: AB_2629447Rabbit monoclonal anti-phospho -Akt(S473)Cell Signaling Tech. (New England Biolabs, Hitchin, UK)Cat #4060, D9E; RRID: AB_2315049Rabbit polyclonal anti-phospho-LAT(Y191)Cell Signaling Tech. (New England Biolabs, Hitchin, UK)Cat #3584; AB_2157728Rabbit polyclonal anti-phospho-PLCγ2(Y759)Cell Signaling Tech. (New England Biolabs, Hitchin, UK)Cat #3874; RRID: AB_2163714Rabbit polyclonal phospho-Syk(Y525/526)Cell Signaling Tech. (New England Biolabs, Hitchin, UK)Cat #2711; RRID: AB_2197215Rabbit polyclonal anti-RacCell Signaling Tech. (New England Biolabs, Hitchin, UK)Cat #2465; RRID: AB_2176152Rabbit polyclonal anti-Cdc42Cell Signaling Tech. (New England Biolabs, Hitchin, UK)Cat #2462; RRID: AB_2078085Rat monoclonal anti-glycoprotein VI (FITC-conjugated)Emfret ANALYTICS (Wurzberg, Germany)JAQ1; RRID: AB_2827531Mouse monoclonal anti-CD62P (FITC-conjugated)Emfret ANALYTICS (Wurzberg, Germany)WugE9; RRID: AB_2890922Rat monoclonal anti-CD41 (FITC-conjugated)Bio-Rad AbD Serotec (Kidlington, UK)MWReg30; RRID: AB_323512Thrombin from Bovine plasmaSigma (Merck-Millipore)Thrombin, Human Plasma, High Activity#605195Peroxidase-conjugated and far-red/infrared secondary antibodiesJackson Immunoresearch (Stratech Scientific Ltd, Ely, UK)N/ABiological samplesCollagen Reagens HORM® SuspensionTakeda (Linz, Austria)N/AChemicals, peptides, and recombinant proteinsCross-linked collagen-related peptideTriple Helical Peptides (Prof Richard Farndale)CRP-XLProtease activated receptor 4 peptide-amide, AYPGKFAbcamPAR-4-AP, ab120179Enhanced chemiluminescent detection reagentsGE Healthcare (Amersham, UK)RPN3004NuPAGE SDS–PAGE sample bufferInvitrogen (Paisley, UK)NP0007cOmplete™ protease inhibitor cocktail tabletsRoche (West Sussex, UK)Cat 11 697 498 001PhosStopTMRoche (West Sussex, UK)Cat 49 068 450 01Chrono-Lume® reagentChrono-Log CorpCat P/N395ATP standardChrono-Log CorpCat P/N 387Fura-PE3CalBioChem (Merck-Millipore)Cat 344911P-F127Invitrogen (ThermoFisher)Cat P3000MPFatty Acid Free (FAF)-BSASigma (Merck-Millipore)Cat 03117057001Prostaglandin E1Sigma (Merck-Millipore)Cat P5515Adenosine nucleotide phosphataseSigma (Merck-Millipore)Cat A6535IndomethacinSigma (Merck-Millipore)Cat I7378Glutathione Sepharose™ 4BCytivaCat 17075601Experimental models: Organisms/strainsMouse: Pik3cbˆtm1.1Jdoˆ/Pik3cbˆtm1.1Jdoˆ mice (p110β RBD knock-in mice), expressing endogenous p110β with S205D and K224A substitutions in the Rho-binding domain; mixed C57BL/6J;129/Sv backgroundC57BL/6JProf Professor Len Stephens (Babraham Institute, Cambridge, UK)Have previously been described (16).Software and algorithmsGraphPad Prism 10.6.0DotMaticsN/AImageJ 1.54pNIHN/AFACSDiva v9.0.1BDN/AAggrolink 5.2.3ChronologN/A REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesRabbit monoclonal anti-phospho-Akt(T308)Cell Signaling Tech. (New England Biolabs, Hitchin, UK)Cat #13038, D25E6; RRID: AB_2629447Rabbit monoclonal anti-phospho -Akt(S473)Cell Signaling Tech. (New England Biolabs, Hitchin, UK)Cat #4060, D9E; RRID: AB_2315049Rabbit polyclonal anti-phospho-LAT(Y191)Cell Signaling Tech. (New England Biolabs, Hitchin, UK)Cat #3584; AB_2157728Rabbit polyclonal anti-phospho-PLCγ2(Y759)Cell Signaling Tech. (New England Biolabs, Hitchin, UK)Cat #3874; RRID: AB_2163714Rabbit polyclonal phospho-Syk(Y525/526)Cell Signaling Tech. (New England Biolabs, Hitchin, UK)Cat #2711; RRID: AB_2197215Rabbit polyclonal anti-RacCell Signaling Tech. (New England Biolabs, Hitchin, UK)Cat #2465; RRID: AB_2176152Rabbit polyclonal anti-Cdc42Cell Signaling Tech. (New England Biolabs, Hitchin, UK)Cat #2462; RRID: AB_2078085Rat monoclonal anti-glycoprotein VI (FITC-conjugated)Emfret ANALYTICS (Wurzberg, Germany)JAQ1; RRID: AB_2827531Mouse monoclonal anti-CD62P (FITC-conjugated)Emfret ANALYTICS (Wurzberg, Germany)WugE9; RRID: AB_2890922Rat monoclonal anti-CD41 (FITC-conjugated)Bio-Rad AbD Serotec (Kidlington, UK)MWReg30; RRID: AB_323512Thrombin from Bovine plasmaSigma (Merck-Millipore)Thrombin, Human Plasma, High Activity#605195Peroxidase-conjugated and far-red/infrared secondary antibodiesJackson Immunoresearch (Stratech Scientific Ltd, Ely, UK)N/ABiological samplesCollagen Reagens HORM® SuspensionTakeda (Linz, Austria)N/AChemicals, peptides, and recombinant proteinsCross-linked collagen-related peptideTriple Helical Peptides (Prof Richard Farndale)CRP-XLProtease activated receptor 4 peptide-amide, AYPGKFAbcamPAR-4-AP, ab120179Enhanced chemiluminescent detection reagentsGE Healthcare (Amersham, UK)RPN3004NuPAGE SDS–PAGE sample bufferInvitrogen (Paisley, UK)NP0007cOmplete™ protease inhibitor cocktail tabletsRoche (West Sussex, UK)Cat 11 697 498 001PhosStopTMRoche (West Sussex, UK)Cat 49 068 450 01Chrono-Lume® reagentChrono-Log CorpCat P/N395ATP standardChrono-Log CorpCat P/N 387Fura-PE3CalBioChem (Merck-Millipore)Cat 344911P-F127Invitrogen (ThermoFisher)Cat P3000MPFatty Acid Free (FAF)-BSASigma (Merck-Millipore)Cat 03117057001Prostaglandin E1Sigma (Merck-Millipore)Cat P5515Adenosine nucleotide phosphataseSigma (Merck-Millipore)Cat A6535IndomethacinSigma (Merck-Millipore)Cat I7378Glutathione Sepharose™ 4BCytivaCat 17075601Experimental models: Organisms/strainsMouse: Pik3cbˆtm1.1Jdoˆ/Pik3cbˆtm1.1Jdoˆ mice (p110β RBD knock-in mice), expressing endogenous p110β with S205D and K224A substitutions in the Rho-binding domain; mixed C57BL/6J;129/Sv backgroundC57BL/6JProf Professor Len Stephens (Babraham Institute, Cambridge, UK)Have previously been described (16).Software and algorithmsGraphPad Prism 10.6.0DotMaticsN/AImageJ 1.54pNIHN/AFACSDiva v9.0.1BDN/AAggrolink 5.2.3ChronologN/A Experimental model and study participant details All animal procedures complied with the UK Animals (Scientific Procedures) Act 1986, were approved by local research ethics and mice bred for this purpose under the U.K. Home Office project license (PPL30/3445). Mice expressing endogenous p110β harboring two mutations (S205D and K224A) in the Ras Binding Domain (RBD) of the Pik3cb gene (PI3 kinase p110β KI) have previously been described16 and were kindly provided by Professor Len Stephens (Babraham Institute, Cambridge, UK). Mice were maintained on a C57BL/6J background under specific-pathogen-free conditions at University of Bristol’s Animal Services Unit (ASU). Age- and sex-matched littermates (8–14 weeks old) were used as controls. Genotyping was performed by PCR on tail-tip DNA using the following primers: p110β-RBD-Forward primer: AATCACCTAGGAGCAGGGTCC and p110β-RBD-Reverse Primer: AGTGACTGACTGTCACTGCAGG, which generates products sizes for wild type of 160bp and RBD mutant of 190 bp. Animals were housed under a 12-h light/dark cycle with ad libitum access to food and water. For human participants, blood donations were collected from healthy, drug free volunteers according to local NHS research ethics approval (REC ref. 20/SC/0222) and the declaration of Helsinki. Samples were obtained from five healthy donors (three females and two males), aged between 25 and 39 years. Human participants were not allocated to separate experimental groups. Instead, platelets isolated from each volunteer were tested under all experimental conditions, with each participant serving as their own control. The sample size (n = 5) and further details are reported in the corresponding legend of Figure S2. Method details Murine platelet isolation All procedures were approved by the University of Bristol Animal Welfare and Ethical Review Body and conducted in accordance with the Animals (Scientific Procedures) Act 1986. Mice (8–14 weeks old) were sacrificed by rising CO2 inhalation, and blood was drawn by cardiac puncture into a syringe containing 4% trisodium citrate (1:9, v/v) before addition of acidified citrate dextrose (ACD, 2.5% sodium citrate dihydrate, 1.5% D-glucose, 0.4% citric acid) at 1/7th final volume. The volume was then adjusted to 2 mL with modified HEPES-Tyrode (145 mM NaCl, 3 mM KCl, 0.5 mM Na2HPO4, 1 mM MgSO4, 10 mM HEPES, pH 7.2, 0.1% (w/v) D-glucose) containing 0.1 (v/v) ACD and centrifuged at 180 g in a swing bucket rotor for 5 min (1000 RPM, Heraeus Megafuge 11). The platelet rich fraction (PRP) was removed and the whole blood was readjusted back to 2 mL with modified HEPES-Tyrode containing 0.1 (v/v) ACD and centrifuged again at 180g. Successive centrifugation was repeated up to three times and PRP pooled. Platelets were pelleted by centrifugation of PRP at 720 g for 5 min (2000 RPM, Heraeus Megafuge 11), in the presence of 10 μM indomethacin, 140 nM PGE1 and apyrase (0.02 U/ml). Pelleted platelets were resuspended in modified HEPES-Tyrode containing 10 μM indomethacin and 0.02 U/ml apyrase. Platelets were counted using a Z1 Coulter particle counter (Beckman Coulter, High Wycombe, UK), diluted to 4x108 platelets/ml and rested for at least 30 min at 30°C prior to the experiment. Human platelet isolation The blood was taken from healthy volunteers into 4% (w/v) trisodium citrate vacutainers. This blood was then centrifuged for 17 min at 1000 rpm (180xg) to yield platelet rich plasma (PRP). The PRP was supplemented with Acid Citrate Dextrose (ACD, 2.5% sodium citrate dihydrate, 1.5% D-glucose, 0.4% citric acid) (1/7 v/v) and then centrifuged to pellet the platelets. The platelet poor supernatant was then removed, and the pellet resuspended in CGS (13 mM trisodium citrate, 22 mM glucose, 120 mM NaCl supplemented with 0.02U/ml apyrase). The platelets were then again spun at 1700rpm (520xg) for 10 min, the supernatant was removed and the pellet resuspended again in freshly added CGS (supplemented with 0.02U/ml apyrase). A final spin was completed at 1700 rpm (520xg) for 10 min. The CGS supernatant was removed and the platelet pellet resuspended in a 1 mL of HT (145 mM NaCl, 3 mM KCl, 0.5 mM Na2HPO4, 1 mM MgSO4, 10 mM HEPES, pH 7.2, 0.1% glucose (w/v), supplemented with 0.02U/ml apyrase) before further dilution to a concentration of 4x108 platelets/ml using a Beckman-Z1 counter (Beckman-Coulter, High Wycombe, UK). Flow cytometry – murine platelets For flow cytometry assays, washed platelets were diluted to 2×107 cells/ml in modified HEPES-Tyrode buffer and experiments were conducted under non stirring conditions. For determination of activation of integrin αIIbβ3 and surface expression of P-selectin, 35 μL aliquots of platelets were incubated with 5 μL agonist (CRP-XL and PAR-4-AP, AYPGKF) at appropriate concentrations for 10 min in the presence of 5 μL of the PE-conjugated activation state specific antibody (Jon/A) and 5 μL FITC conjugated anti-CD62-P antibody (WugE9) prior to fixation with 1% formaldehyde for 30 min. Integrin αIIbβ3 activation and P-selectin expression were subsequently assessed by two color analysis using a BD Accuri C6+ flow cytometer using FACSDiva software, and a total of 10.000 platelet events per sample were collected. Data is expressed as Mean Fluorescence Intensity. Flow cytometry – human platelets For flow cytometry assays, washed platelets were diluted to 2 × 107 cells/ml in modified HEPES-Tyrode buffer and experiments were conducted under non stirring conditions. For determination of activation of integrin αIIbβ3 and surface expression of P-selectin, 35 μL aliquots of platelets were incubated with 5 μL agonist (CRP-XL and TRAP6) at appropriate concentrations for 10 min in the presence of 5 μL of the integrin αIIbβ3 (PAC-1) and 2.5 μL PE conjugated anti-CD62-P antibody (AK-4) prior to fixation with 2% formaldehyde for 15 min. Integrin αIIbβ3 activation and P-selectin expression were subsequently assessed by two color analysis using a BD Accuri C6+ flow cytometer using FACSDiva software, and a total of 10.000 platelet events per sample were collected. Data is expressed as Mean Fluorescence Intensity. Aggregation Washed platelets (2×108/mL) were stimulated with CRP-XL (1,2 and 5 μg/mL), the PAR-4 peptide AYPGKF (75 and 100 μM) or 0.2 U/ml thrombin and aggregation was monitored in a Chrono-log 590-2A aggregometer at 37°C with continuous stirring at 1200 rpm as previously described.51 Aggregation is recorded for 5 min after addition of the agonist using Aggrolink Version 5.2.3 software (Chronolog). Data is expressed as the percentage of maximal aggregation. ATP secretion Platelet dense granule secretion was assessed by measuring ATP release using a luciferin/luciferase-plate based luminescence assay. ATP secretion was assayed using platelets at 2x108/mL incubated with 1% Chrono-Lume reagent (Chrono-Log Corp., Cat P/N395) at 37°C by monitoring luminescence in a TECAN Infinite M200 Pro plate reader (Tecan Group Ltd., Switzerland) for 5 min following agonist addition. Results were calibrated and normalised by subsequent addition of 0.8 nM ATP standard (Chrono-Log Corp., Cat P/N 387) to each well. Calcium signaling Intracellular Ca2+ mobilisation was assayed using a TECAN M200 plate reader monitoring the fluorescent ratiometric dye FuraPE3 as previously described.52 Briefly, platelets were prepared as described in the section platelet isolation and the pellet was resuspended and washed twice in Citrate Glucose Saline buffer (CGS, 3.8% Trisodium Citrate Dihydrate, 120 mM NaCl and 30 mM D-Glucose). After the second resuspension in CGS, platelets were incubated with 4 μM Fura-PE3 for 1 h in the presence of 0.35% fatty acid-free (FAF)-BSA. Platelet were subsequently pelleted, resuspended in modified HEPES-Tyrode buffer and diluted to 1 × 108/mL prior to the addition of 1 mM CaCl2 and incubation at 37°C. Ratiometric measurements (340/380 nm) were taken every 10.9 s over a 5 min period using an Infinite 200 PRO multimode reader (TECAN, Reading, UK) following addition of the agonist, with 1 s orbital shake at maximum velocity between cycles. Average baseline cycles were subtracted from the readings and the Area Under the Curve (AUC) calculated for each condition. Platelet spreading 96-well glass-bottomed plates were coated with 100 μg/ml fibrinogen (2h RT) followed by blocking with 3% (w/v) FAF-BSA (1 h, RT). Washed platelets (4 × 108/mL) were preincubated with inhibitor or vehicle control for 10 min. Platelets were subsequently added to the fibrinogen-coated well at a concentration of 2x107/mL in the presence of vehicle, 1 μg/ml CRP or 0.1U/ml Thrombin. After 30 min incubation at 37°C, platelets were fixed in 2% glutaraldehyde, stained with ActinGreen and imaged on a Leica widefield microscope. Immunoblotting and small G-protein assays Platelets were stimulated with various agonist for different time periods and either lysed in 4x NuPage SDS-PAGE sample buffer (Invitrogen (Paisley, UK) or extracted 50:50 (v/v) in 2x Rac/Cdc42 lysis Buffer (50 mM HEPES, 400 mM NaCl, 5 mM MgCl, 2% NP-40, 20% glycerol) with added PhosSTOP (Roche (West Sussex, UK) and 1 mM DTT. Nupage lysates were subsequently Western blotted for pT308 Akt, pS473 Akt, pY191 LAT, PpY525/526 Syk, pY759 PLCγ, pPLeckstrin, and pT180/Y182 p38. Clarified Rac/Cdc42 lysates were incubated with GST-PAK1 RBD (20–30 μg/200 μL lysate) and Gluthathione-Sepaharose 4B (10 μL GS4B/200 μL lysate) and rotated at 4°C for 60 min GS4B beads were washed 3x in ice-cold 1x lysis buffer (25 mM HEPES, 200 mM NaCl, 2.5 mM MgCl, 1% NP-40, 10% glycerol) and protein eluted by adding 20 μL 1.5x NuPage SDS-PAGE sample buffer. Samples were heated at 70°C for 10 min and analyzed by Western blotting for Rac and CDC42, as described previously.51 NuPage Lysates were subjected to Western blotting for talin, which served as a loading control for the phosphoblots and a protein input control for Rac/Cdc42 activity assays. Quantification and statistical analysis Data were analyzed and fitted using GraphPad Prism 10 (GraphPad Software, San Diego, CA, USA). All data are presented as the mean ± SEM of at least three independent biological replicates. Concentration-response curves were fitted with a four-parameter logistic (variable slope) equation. Statistical testing was performed using either two-tailed Student’s t test, Wilcoxon signed-rank test for two group analysis or two-way ANOVA followed by Bonferroni’s post-hoc correction for multiple comparison where appropriate. Data normality was assessed using the D’Agostino–Pearson omnibus K2 test. A p value of <0.05 was considered statistically significant.